Form 8-K CYTORI THERAPEUTICS, For: Mar 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- BOJ eyeing September rate hike, faster pace of tightening, sources say
Roth Capital Remains Bullish on Cytori Therapeutics (CYTX) Following Q4 Results; Affirms at 'Buy'
March 4, 2016 12:36 PM ESTRoth Capital reaffirmed its Buy rating and $1.50 price target on Cytori Therapeutics (Nasdaq: CYTX) following Q4 results and update issued Thursday night. Cytori reported a relatively inline Q4 loss of $0.03 per share.
Analyst Joseph Pantginis offered the... More
Cytori Therapeutics (CYTX) Tops Q4 EPS by 1c
March 3, 2016 4:28 PM ESTCytori Therapeutics (NASDAQ: CYTX) reported Q4 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.56 million versus the consensus estimate of $3.18 million.
2016 Financial Guidance
Operating cash burn within a... More